Should I buy Illumina, Inc. (ILMN) stock or is it too late?

Illumina, Inc. · Health Care · price $228

See the full Illumina, Inc. (ILMN) profile

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Guggenheim — 77% of its targets hit on this sector (52 calls tested). It aims for $226 (-0.7 %), call made on August 1, 2026, maturing on August 1, 2027 (27 d ago).

The 6 reliable analysts $218-4.5 %

The 5 other firms $210-7.8 %

How to read it: the 6 reliable firms are not filtered by optimism — 1 aim above the price, 5 below, hence their $218 median. “The 5 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Illumina, Inc.

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Guggenheim	100 %	+33.9 %	5	$226 -1%
Citigroup	60 %	+9.7 %	15	$113 -50%
Argus Research	50 %	+9.1 %	6	$150 -34%
Evercore ISI Group	43 %	+7.9 %	7	$200 -12%
Barclays	55 %	+7.4 %	20	$160 -30%
Piper Sandler	45 %	+3.6 %	20	$225 -1%
Stephens & Co.	38 %	-1.3 %	8	$105 -54%
Stifel	36 %	-3.8 %	11	$225 -1%

In short — Should you invest in Illumina, Inc.? Is it too late, still worth it? Analysts are fairly positive (64% buy, median target $210, i.e. -8%). But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

64% of analysts rate it a buy (Hold consensus, 11 ratings) — a sign of market conviction.

⚠️ Reasons to hesitate

Even the most reliable firm on ILMN, Baird (100% hit rate, 3 scored calls), only targets $109 (call made on October 31, 2025, maturing on October 31, 2026) (-52%) in its most recent call. The stock may already have run past its target.
The consensus is not unanimous: of 11 ratings, 2 are neutral and 2 are sells.
Limited upside: the median target is only -8% from the current price.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.

The analyst consensus on ILMN

Median target $210 (-8%) · 11 ratings · Hold consensus

Strong Buy00%

Buy764%

Hold218%

Sell218%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Illumina, Inc. now?

We won't decide for you. The facts: 64% of analysts rate it a buy, median target $210 (-8%), and Baird (most reliable on ILMN, 100%) targets $109. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in Illumina, Inc.?

The stated upside is small: the median target ($210) sits just -8% from the price ($228) (most reliable on ILMN: Baird, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Illumina, Inc. still worth investing in?

It depends on the gap between the price ($228) and its estimated value: analysts target $210 on median (-8%), with 64% buys (most reliable on ILMN: Baird, 100%). Cross-check with their real reliability on ILMN and the cautions above. Information, not advice.

What's the main risk in buying ILMN?

Even the most reliable firm on ILMN, Baird (100% hit rate, 3 scored calls), only targets $109 (call made on October 31, 2025, maturing on October 31, 2026) (-52%) in its most recent call. The stock may already have run past its target.

→ Go deeper: the full Illumina, Inc. profile (consensus, analyst reliability, price target, performance).